Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05856981 · ClinicalTrials.gov registry record · Phase 1

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

A Phase 1 study of Endometrial Cancer and Solid Tumor, Adult, sponsored by Sairopa B.V..

Recruiting
Registry status
Phase 1
Development phase
130
Enrollment target
7
Study locations

NCT05856981 is a Phase 1 study of Endometrial Cancer and Solid Tumor, Adult that is actively recruiting participants, run by Sairopa B.V.. The registered enrollment target is 130 participants, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (75% lower). The trial reports 7 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05856981, a Phase 1 study of Endometrial Cancer and Solid Tumor, Adult, is actively recruiting participants, sponsored by Sairopa B.V..

RECRUITING
Registry status
Phase 1
Development phase
130 participants
Enrollment target
7
Study locations

Study Summary

This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monoclonal antibody, as monotherapy and in combination with pembrolizumab (anti-PD-1 antibody).

Conditions Studied

Endometrial Cancer Solid Tumor, Adult Metastatic Solid Tumor Refractory Cancer CRC, Colorectal Cancer NSCLC (Advanced Non-small Cell Lung Cancer) RCC, Clear Cell Adenocarcinoma

Interventions

  • DRUG Pembrolizumab
  • DRUG ADU-1805

Study Locations (7)

Other

  • Grand Hopital de Charleroi (GHdC) - Hopital Notre Dame - Charleroi
  • Hosp 12 de Octubre - Madrid
  • Hospital General Universitario Gergorio Maranon - Madrid

Michigan

  • Henry Ford Cancer Institute - Detroit

Missouri

  • Washington University Medical Campus - St Louis

Ohio

  • Gabrail Cancer & Research Center - Canton

Virginia

  • Virginia Cancer Specialists - Fairfax

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2023-04-03
Est. Completion 2027-07
Phase Phase 1

Sponsor

Sairopa B.V.

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05856981

The ClinicalTrials.gov registry entry for NCT05856981 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (75% lower). The listed sponsor is Sairopa B.V., which has 1 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT05856981 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Other, Michigan, Missouri.

Frequently Asked Questions

What is clinical trial NCT05856981 about?

NCT05856981 is a clinical study titled "Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors". This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monoclonal antibody, as monotherapy and in combination with pembrolizumab (anti-PD-1 antibody).

What is the current status of trial NCT05856981?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2023-04-03. Estimated completion is 2027-07.

What conditions does trial NCT05856981 study?

This clinical trial studies the following conditions: Endometrial Cancer, Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer, CRC, Colorectal Cancer.

What interventions are being tested in trial NCT05856981?

The interventions under investigation include: Pembrolizumab (DRUG), ADU-1805 (DRUG).

Who is sponsoring clinical trial NCT05856981?

This trial is sponsored by Sairopa B.V., which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05856981 being conducted?

This trial has 7 study locations across Michigan, Missouri, Ohio, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Endometrial Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Endometrial Cancer

All registered trials for this condition

Solid Tumor, Adult

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.